Cylembio + Pembrolizumab Shows PFS Benefit in Advanced Melanoma Phase 3 Trial
August 11, 2025
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab)…
The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.
If you have an idea for a future article, please reach out to us on our contact page!
